Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive
View HTML
Toggle Summary ImmunoGen, Inc. Announces Results from Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Presentations at 2012 ASCO Annual Meeting on Product Candidates with the Company's TAP Technology
— Trastuzumab emtansine (T-DM1) EMILIA Phase III data selected for plenary session; SAR3419 data and additional trastuzumab emtansine data also being reported — WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops targeted antibody-based
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Bank of America Merrill
View HTML
Toggle Summary ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
Trastuzumab emtansine (T-DM1) progress includes achievement of progression-free survival (PFS) endpoint in lead Phase III trial for HER2+ metastatic breast cancer. Data from this trial and the Phase II safety trial in (neo)adjuvant setting submitted to ASCO for presentation.
View HTML